Difference between revisions of "Bone sarcoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Ewing's sarcoma" to "Ewing sarcoma")
m (Text replacement - "http://www.esmo.org/" to "https://www.esmo.org/")
 
(25 intermediate revisions by 3 users not shown)
Line 1: Line 1:
−
{| class="wikitable" style="text-align:center; width:50%;"
+
<span id="BackToTop"></span>
−
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
−
|-
+
[[#top|Back to Top]]
−
|style="background-color:#F0F0F0"|[[File:jim_chen.jpeg|frameless|upright=0.3|center]]
+
</div>
−
|<big>[[User:Jimchen|James L. Chen, MD, MS]]<br>The Ohio State University<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn]
+
{{#lst:Editorial board transclusions|sarcoma}}
−
|-
 
−
|}
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
−
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
+
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
−
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
+
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 
<big>Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the [[:Category:Bone sarcomas|category page]] for links to other sarcoma types or use one of these links:
 
<big>Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the [[:Category:Bone sarcomas|category page]] for links to other sarcoma types or use one of these links:
 
*[[Ewing sarcoma]]
 
*[[Ewing sarcoma]]
 +
*[[Giant-cell tumor of bone]]
 
*[[Osteosarcoma]]
 
*[[Osteosarcoma]]
 
</big>
 
</big>
 
=Guidelines=
 
=Guidelines=
−
==[http://www.esmo.org/ ESMO]==
+
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
−
*[http://annonc.oxfordjournals.org/content/25/suppl_3/iii113.full.pdf+html Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.] [https://www.ncbi.nlm.nih.gov/pubmed/25210081 PubMed]
+
==[https://www.esmo.org/ ESMO]/EURACAN/GENTURIS/PaedCan==
−
==[https://www.nccn.org/ NCCN]==
+
*'''2021:''' Strauss et al. [https://doi.org/10.1016/j.annonc.2021.08.1995 Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/34500044/ PubMed]
−
*[https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf NCCN Guidelines - Bone Cancer]
+
**'''2018:''' Casali et al. [https://doi.org/10.1093/annonc/mdy310 Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/30285218/ PubMed]
 +
**'''2014:''' [https://doi.org/10.1093/annonc/mdu256 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/25210081/ PubMed]
 +
**'''2012:''' [https://doi.org/10.1093/annonc/mds254 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/22997441/ PubMed]
 +
**'''2010:''' Hogendoorn et al. [https://doi.org/10.1093/annonc/mdq223 Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555083/ PubMed]
 +
 
 +
==NCCN==
 +
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418 NCCN Guidelines - Bone Cancer]
 +
*'''2013:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2013.0088 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/23744868/ PubMed]
 +
*'''2010:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2010.0051 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/20581300/ PubMed]
 +
*'''2007:''' Biermann et al. [https://doi.org/10.6004/Jnccn.2007.0037 Bone cancer.] [https://pubmed.ncbi.nlm.nih.gov/17442233/ PubMed]
 +
*'''2005:''' Biermann et al. Bone cancer clinical practice guidelines. [https://pubmed.ncbi.nlm.nih.gov/19817025/ PubMed]
  
 
=Chondrosarcoma, all lines of therapy=
 
=Chondrosarcoma, all lines of therapy=
Line 27: Line 36:
 
*Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]]
 
*Dedifferentiated chondrosarcoma has been treated with [[Osteosarcoma|osteosarcoma regimens]]
  
−
=Giant-cell tumor of bone, all lines of therapy=
+
=Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy=
−
==Denosumab monotherapy {{#subobject:65e2b|Regimen=1}}==
+
*Undifferentiated pleomorphic sarcoma (UPS) of bone has been treated with [[Osteosarcoma|osteosarcoma regimens]]
−
{| class="wikitable" style="float:right; margin-left: 5px;"
 
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
−
 
 
−
===Regimen {{#subobject:f50a28|Variant=1}}===
 
−
{| class="wikitable" style="width: 100%; text-align:center;"
 
−
!style="width: 50%"|Study
 
−
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext Thomas et. al 2010]
 
−
|style="background-color:#91cf61"|Phase II
 
−
|-
 
−
|}
 
−
====Chemotherapy====
 
−
*[[Denosumab (Xgeva)]] as follows:
 
−
**Cycle 1: 120 mg SC once per day on days 1, 8, 15
 
−
**Cycle 2 onwards: 120 mg SC once on day 1
 
−
 
 
−
====Supportive medications====
 
−
*Calcium 500 mg PO once per day
 
−
*Vitamin D 400 IU PO once per day
 
−
 
 
−
'''28-day cycles, given until complete tumor resection, progression of disease, or patient choice'''
 
−
 
 
−
===References===
 
−
# Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20149736 PubMed]
 
−
 
 
−
=Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy=
 
−
*Malignant fibrous histiocytoma (MFH) of bone has been treated with [[Osteosarcoma|osteosarcoma regimens]]
 
  
 
[[Category:Bone sarcoma regimens]]
 
[[Category:Bone sarcoma regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Bone sarcomas]]
 
[[Category:Bone sarcomas]]

Latest revision as of 17:51, 23 June 2024

Back to Top

Section editor
Elizabethdavis2.jpg
 Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN, USA
0 regimens on this page
0 variants on this page


Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ESMO/EURACAN/GENTURIS/PaedCan

NCCN

Chondrosarcoma, all lines of therapy

Undifferentiated pleomorphic sarcoma (UPS) of bone, all lines of therapy

Retrieved from "https://hemonc.org/w/index.php?title=Bone_sarcoma&oldid=86505"